HK Stock Market Move | EDGE MEDICAL-B(02675) rose by over 9%. The National Medical Insurance Administration is comprehensively promoting the approval of operation fees for Siasun Robot&Automation and other procedures.

EDGE MEDICAL-B (02675) rose more than 9%, as of the time of publication, it rose by 9.09%, at 64.8 Hong Kong dollars, with a turnover of 23.0585 million Hong Kong dollars. On the news front, on January 20, the National Medical Insurance Bureau officially released the "Guidelines for the Project Approval of Surgical and Therapeutic Assistant Operation Medical Service Price Projects (Trial)", focusing on cutting-edge medical technology achievements, around 3D printing, trace-enhanced imaging, energy instruments, intraoperative imaging guidance, medical technology innovation achievements such as robotic arms and remote surgery, to carry out unified price project approval, standardize the formation of 37 price items, 5 additional items, and 1 expansion item. Founder believes that the implementation of this guideline will promote the standardized approval and fee pricing of surgical Siasun Robot & Automation in various provinces, promote the clinical popularization of innovative technology, drive the procurement of terminal equipment and the release of surgical assistance demand, and recommends focusing on domestic surgical Siasun Robot & Automation leading enterprises like Jingfeng Medical. Public information shows that Jingfeng Medical is an advanced surgical Siasun Robot & Automation company in the domestic medical device industry, specializing in the design, development, and manufacturing of surgical Siasun Robot & Automation. According to data from Frost & Sullivan, Jingfeng Medical is the first company in China and the second company globally to obtain registration approval for both multi-port endoscopic surgery Siasun Robot & Automation, single-port endoscopic surgery Siasun Robot & Automation, and natural orifice surgery Siasun Robot & Automation.